Cite

HARVARD Citation

    Wang, V. et al. (2017). Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. Journal for immunotherapy of cancer. 5 (1), p. . [Online]. 
  
Back to record